All Outputs (2)

Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice (2015)
Journal Article
Pereira, M., Jeyabalan, J., Jorgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., …Chenu, C. (2015). Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. BONE, 81, 459-67. https://doi.org/10.1016/j.bone.2015.08.006

Some anti-diabetic therapies can have adverse effects on bone health and increase fracture risk. In this study, we tested the skeletal effects of chronic administration of two Glucagon-like peptide-1 receptor agonists (GLP-1RA), increasingly used for... Read More about Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.

Acidosis Is a Key Regulator of Osteoblast Ecto-Nucleotidase Pyrophosphatase/Phosphodiesterase 1 (NPP1) Expression and Activity (2015)
Journal Article
Orriss, I. R., Key, M. L., Hajjawi, M. O. R., Millan, J. L., & Arnett, T. R. (2015). Acidosis Is a Key Regulator of Osteoblast Ecto-Nucleotidase Pyrophosphatase/Phosphodiesterase 1 (NPP1) Expression and Activity. Journal of Cellular Physiology, 230(12), 3049-3056. https://doi.org/10.1002/jcp.25041

Previous work has shown that acidosis prevents bone nodule formation by osteoblasts in vitro by inhibiting mineralisation of the collagenous matrix. The ratio of phosphate (Pi) to pyrophosphate (PPi) in the bone microenvironment is a fundamental regu... Read More about Acidosis Is a Key Regulator of Osteoblast Ecto-Nucleotidase Pyrophosphatase/Phosphodiesterase 1 (NPP1) Expression and Activity.